Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Rabusertib

b2c4e856-50c2-5251-a1d6-63ac6f25c90a · FDA trials Discontinued after Phase II · targets CHK1

Rabusertib

MeasuredReference

Rabusertib targets CHEK1, RAF1, CAMK2A. Strongest hallmark effect: evading apoptosis.

Primary targets

CHEK1RAF1CAMK2ARPS6KA2CAMK2D

Top hallmarks

  • evading apoptosis1.6k
  • proliferation1.5k
  • tumor promoting inflammation1.5k

Top pathways disrupted

No pathway data.

Resistance landscape — Rabusertib

MeasuredReference

1 known oncogenic variants exist on Rabusertib's top targets — see detail for inhibition impact.

Open in new tab